Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

Conditions: Metastatic Colorectal Cancer Interventions: Drug: Retifanlimab; Biological: Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform; Drug: N-803; Drug: SX-682 Sponsors: National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials